Carboplatin: current status and future prospects.

Suppr

超能文献

作者信息

Canetta R, Bragman K, Smaldone L, Rozencweig M

机构信息

Bristol-Myers Company, Pharmaceutical Research and Development, Wallingford, CT 06492-7600.

出版信息

Cancer Treat Rev. 1988 Jun;15 Suppl B:17-32. doi: 10.1016/0305-7372(88)90031-x.

DOI:10.1016/0305-7372(88)90031-x

PMID:2841021

Abstract

摘要

相似文献

Carboplatin: current status and future prospects.

Cancer Treat Rev. 1988 Jun;15 Suppl B:17-32. doi: 10.1016/0305-7372(88)90031-x.

Carboplatin: the clinical spectrum to date.

Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36. doi: 10.1016/0305-7372(85)90027-1.

Carboplatin, an active drug in advanced head and neck cancer.

Cancer Treat Rep. 1986 Oct;70(10):1173-6.

[A phase II study of carboplatin in lung cancer. The Carboplatin Cooperative Study Group].

Gan To Kagaku Ryoho. 1988 Sep;15(9):2781-5.

Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung.

Eur J Cancer. 1993;29A(8):1216. doi: 10.1016/s0959-8049(05)80327-2.

Carboplatin: the clinical evaluation strategy.

Cancer Treat Rev. 1985 Sep;12 Suppl A:137-44. doi: 10.1016/0305-7372(85)90028-3.

[Experimental study on the anti-tumor effects of CDDP derivatives on head and neck squamous cell carcinoma cell lines].

Gan To Kagaku Ryoho. 1988 Sep;15(9):2811-4.

Phase II study of carboplatin in patients with nonresected lung cancer. Japan Cooperative Oncology Group on Lung Cancer.

Cancer Chemother Pharmacol. 1990;26(2):101-4. doi: 10.1007/BF02897253.

Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.

J Clin Oncol. 1986 Oct;4(10):1506-9. doi: 10.1200/JCO.1986.4.10.1506.

Whither carboplatin.

J Clin Oncol. 1987 Jun;5(6):984-6. doi: 10.1200/JCO.1987.5.6.984.

引用本文的文献

From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.

Drugs. 2025 Apr;85(4):487-503. doi: 10.1007/s40265-025-02152-6. Epub 2025 Feb 12.

Inhibition of transcription by platinum antitumor compounds.

Metallomics. 2009;1(4):280-91. doi: 10.1039/b907567d.

Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.

J Ovarian Res. 2009 Jan 14;2:2. doi: 10.1186/1757-2215-2-2.

Clinical pharmacokinetics and administration of established platinum drugs.

Drugs. 2000;59 Suppl 4:19-27. doi: 10.2165/00003495-200059004-00003.

Clinical pharmacokinetics and dose optimisation of carboplatin.

Clin Pharmacokinet. 1997 Sep;33(3):161-83. doi: 10.2165/00003088-199733030-00002.

Preoperative chemotherapy with carboplatin alone in high risk medulloblastoma.

Childs Nerv Syst. 1995 Oct;11(10):574-8. doi: 10.1007/BF00300995.

The antitumor activity of the platinum complex D-17872 is associated with tumor cell differentiation.

Cancer Chemother Pharmacol. 1993;32(2):123-8. doi: 10.1007/BF00685614.

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Br J Cancer. 1993 Feb;67(2):396-401. doi: 10.1038/bjc.1993.73.

Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.

Cancer Chemother Pharmacol. 1993;32(6):425-33. doi: 10.1007/BF00685885.

Clinical pharmacokinetics of carboplatin in children.

Cancer Chemother Pharmacol. 1994;33(6):477-83. doi: 10.1007/BF00686504.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验